Eric Hyllengren was named Chief Financial Officer of Tenaya Therapeutics, Inc. As of November 6, 2026, Tenaya Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 29, 2026, naming 1 appointment (Form 8-K, June 29, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Tenaya Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Tenaya Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-29. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Tenaya Therapeutics, Inc. files it.
Also on the record for Tenaya Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 24, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.2% of the class | 5%+ stakes | Source |
| February 26, 2026 | Stake report, Schedule 13D/A, by The Column Group III, LP | 23.1% of the class | 5%+ stakes | Source |
| February 12, 2026 | Stake report, Schedule 13D/A, by The Column Group III, LP | 25.4% of the class | 5%+ stakes | Source |
| December 17, 2025 | Stake report, Schedule 13D/A, by The Column Group III, LP | 23.1% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Woodline Partners LP | 4.99% of the class | 5%+ stakes | Source |
| July 31, 2025 | Stake report, Schedule 13G/A, by Empery Asset Management, LP | 4.99% of the class | 5%+ stakes | Source |
| July 16, 2025 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 1.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tenaya Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tenaya Therapeutics, Inc. and the records around it.
Tenaya Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Woodline Partners LP also filed stake reports on 19 other companies: Biohaven Ltd. (Aug 2026), Black Rock Coffee Bar, Inc. (Aug 2026), CalciMedica, Inc. (Aug 2026)
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
Watch Tenaya Therapeutics, Inc.
Get an email when Tenaya Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tenaya Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tenaya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tenaya Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-29 | In | Chief Financial Officer | 8-K, 2026-06-29 |
Who leads Tenaya Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Eric Hyllengren, appointed (filed 2026-06-29).
New leaders reset buying decisions — get the Full Report on Tenaya Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Tenaya Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Tenaya Therapeutics, Inc.Every change, in the filing's words
Appointed: Eric Hyllengren, Chief Financial Officer
Appointment of Chief Financial Officer and Transition of Principal Financial Officer and Principal Accounting Officer On June 29, 2026, Tenaya Therapeutics, Inc. (the "Company") announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026 (the "Commencement Date"), and in such capacity, will serve as the Company's Principal Financial Officer and Principal Accounting Officer beginning on the Commencement Date.
- Prior to joining the Company, Mr. Hyllengren, age 51, served as Chief Financial Officer at Zura Bio Ltd. from July 2025 until April 2026.
- Mr. Hyllengren spent seven years at Atara Biotherapeutics, Inc. ("Atara"), most recently serving in the role of Chief Financial Officer and Chief Operating Officer, from April 2023 and October 2024, respectively, until April 2025, and was previously Atara's Vice President of Finance and Investor Relations from August 2018 until April 2023.
- Earlier in his career, Mr. Hyllengren held roles of increasing responsibility across finance, investor relations, and business development at Amgen Inc., where he was most recently Executive Director of Business Development and Head of Alliance Management from 2017 to 2018.
- Mr. Hyllengren holds a B.B.A. in Finance and Russian from the University of Notre Dame and an M.B.A. in Finance and Strategy from the Kellogg School of Management at Northwestern University.
- Effective as of immediately prior to the Commencement Date, Faraz Ali, M.B.A., the Company's President and Chief Executive Officer, will cease serving as interim Principal Financial Officer, and Tomohiro Higa, the Company's Senior Vice President, Finance, will cease serving as acting interim Principal Accounting Officer.
Tools for this story
Each opens in a new tab, filled in for Tenaya Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.